NEC Corp., of Tokyo, and Transgene SA, of Strasbourg, France, plan to collaborate on an individualized immunotherapy for the treatment for solid cancers, including ovarian cancer and HPV-negative head and neck cancer, using NEC's artificial intelligence technology and Transgene's myvac MVA-based viral vector platform.